/PRNewswire/ Octapharma USA has submitted a Biologics License Application Supplement (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the.
/PRNewswire/ New clinical data from Octapharma s haematology portfolio, including the results of the phase 3 WIL-31 study, will be presented during the.